Aurinia Pharmaceuticals (AUPH) vs Bausch Health Companies (BHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Bausch Health Companies (BHC) over the past year, gaining 40.7% versus a loss of 4.7%. Over five years, AUPH leads with a -21.1% price change compared with -78.8% for BHC. Bausch Health Companies is the larger company by market cap ($2.26 billion vs $2.16 billion), about 1.0 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 15.2x for Aurinia Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | BHC |
|---|---|---|
| Share price | $16.22 | $6.04 |
| Market cap | $2.16B | $2.26B |
| 1-day change | +1.31% | -1.79% |
| YTD return | +1.69% | -13.09% |
| 1-year return | +40.68% | -4.73% |
| 5-year return | -21.15% | -78.80% |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | 1.44 |
| EPS (TTM) | $2.28 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $8.00 |
| 52-week low | $10.90 | $4.33 |
| Distance from 52-week high | -15.74% | -24.50% |
| Analyst consensus | none | hold |
| Avg. price target upside | +10.11% | +24.17% |
| Average volume | 988.90K | 3.24M |
| Shares outstanding | 133.05M | 373.99M |
| Employees | 128 | 20,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed BHC by 45.4 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
AUPH vs BHC FAQ
Which is bigger, Aurinia Pharmaceuticals or Bausch Health Companies?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.26B compared with $2.16B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or BHC?
AUPH returned +40.68% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Bausch Health Companies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.